Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David V Glidden

Showing results (11-20 of 266) with videos related to

Pageof 27
Sort By:
Current Drug Targets|September 1, 2009
Clinical trials for acute kidney injury: design challenges and possible solutionsKathleen D Liu, David V Glidden
Respiratory Care|January 24, 2024
Reply to: Letter Regarding Time to Extubation Among ARDS Subjects With and Without COVID-19 Pneumonia ManuscriptGregory D Burns, David V Glidden
Sexually Transmitted Infections|April 15, 2017
Response to: A double-edged sword: does highly active antiretroviral therapy contribute to syphilis incidence by impairing immunity to <i>Treponema pallidum</i>?David V Glidden, Kenneth Mayer, Robert M Grant
The Lancet. Infectious Diseases|December 4, 2018
Strengthening HIV-prevention trials: a dose of implementation science?Elvin H Geng, David V Glidden, Nancy Padian
Plos One|July 2, 2014
Healthcare utilization and clinical outcomes after catheter ablation of atrial flutterThomas A Dewland, David V Glidden, Gregory M Marcus
Statistical Communications in Infectious Diseases|July 26, 2022
Confidence limits for the averted infections ratio estimated via the counterfactual placebo incidence rateDavid T Dunn, Oliver T Stirrup, David V Glidden
The Lancet. HIV|October 31, 2020
A Bayesian averted infection framework for PrEP trials with low numbers of HIV infections: application to the results of the DISCOVER trialDavid V Glidden, Oliver T Stirrup, David T Dunn
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 16, 2023
Reply to Niu and DrainPeter L Anderson, Mark A Marzinke, David V Glidden
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 16, 2023
Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender WomenPeter L Anderson, Mark A Marzinke, David V Glidden
The Lancet. HIV|August 27, 2016
Pharmacology supports on-demand PrEPDavid V Glidden, Peter L Anderson, Robert M Grant
Pageof 27

Showing results (11-20 of 266) with videos related to

Sort By:
Pageof 27
Current Drug Targets|September 1, 2009
Clinical trials for acute kidney injury: design challenges and possible solutionsKathleen D Liu, David V Glidden
Respiratory Care|January 24, 2024
Reply to: Letter Regarding Time to Extubation Among ARDS Subjects With and Without COVID-19 Pneumonia ManuscriptGregory D Burns, David V Glidden
Sexually Transmitted Infections|April 15, 2017
Response to: A double-edged sword: does highly active antiretroviral therapy contribute to syphilis incidence by impairing immunity to <i>Treponema pallidum</i>?David V Glidden, Kenneth Mayer, Robert M Grant
The Lancet. Infectious Diseases|December 4, 2018
Strengthening HIV-prevention trials: a dose of implementation science?Elvin H Geng, David V Glidden, Nancy Padian
Plos One|July 2, 2014
Healthcare utilization and clinical outcomes after catheter ablation of atrial flutterThomas A Dewland, David V Glidden, Gregory M Marcus
Statistical Communications in Infectious Diseases|July 26, 2022
Confidence limits for the averted infections ratio estimated via the counterfactual placebo incidence rateDavid T Dunn, Oliver T Stirrup, David V Glidden
The Lancet. HIV|October 31, 2020
A Bayesian averted infection framework for PrEP trials with low numbers of HIV infections: application to the results of the DISCOVER trialDavid V Glidden, Oliver T Stirrup, David T Dunn
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 16, 2023
Reply to Niu and DrainPeter L Anderson, Mark A Marzinke, David V Glidden
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 16, 2023
Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender WomenPeter L Anderson, Mark A Marzinke, David V Glidden
The Lancet. HIV|August 27, 2016
Pharmacology supports on-demand PrEPDavid V Glidden, Peter L Anderson, Robert M Grant
Pageof 27